Broadcom named strategic vendor for Walmart virtualization solutions
Investing.com - Morgan Stanley (NYSE:MS) initiated coverage on Trevi Therapeutics (NASDAQ:TRVI) with an Overweight rating and a price target of $18.00 on Thursday. According to InvestingPro data, analyst targets for TRVI range from $13 to $27, with the stock showing impressive momentum, having gained over 164% in the past year.
The investment bank’s research highlights Trevi’s development of Haduvio, an oral extended-release formulation of nalbuphine, which functions as a mixed opioid agonist-antagonist targeted at treating chronic cough. With a market capitalization of $905 million and a strong financial health score according to InvestingPro, Trevi maintains a solid balance sheet with more cash than debt.
Morgan Stanley notes that chronic cough, while seemingly minor, represents a debilitating condition affecting millions of Americans, with current treatment options providing limited relief or carrying significant risks such as abuse potential and respiratory depression.
The firm points to growing pharmaceutical industry interest in the chronic cough treatment space, citing major companies like GSK and Merck (NSE:PROR) that have entered into billion-dollar deals (including potential milestones) for compounds targeting chronic cough.
Trevi’s Haduvio represents a potential new treatment option in this underserved therapeutic area where existing medications offer inadequate solutions for patients suffering from this persistent condition.
In other recent news, Trevi Therapeutics reported its Q2 2025 earnings, showing a net loss that was slightly better than analysts had anticipated. The company posted an earnings per share (EPS) of -$0.09, surpassing the forecasted -$0.10, which resulted in a 10% positive surprise. This development reflects a cautious optimism among investors regarding the company’s financial performance. Despite the negative earnings, the slight EPS beat suggests that Trevi Therapeutics is performing marginally better than expected. These earnings results are a key focus for investors, as they provide insight into the company’s financial health. In addition to the earnings report, no significant mergers or acquisitions were announced. There were also no recent analyst upgrades or downgrades reported for Trevi Therapeutics. These recent developments are crucial for investors monitoring the company’s progress.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.